RSS Alerts

Share

More services

Related Links

Related Stories

  • Psychiatric drugs ‘as effective as other drugs’
    Psychiatric drugs are as effective as drugs used to treat many physical health problems, according to a major review published in the February issue of the British Journal of Psychiatry.
  • Lithium Treatment Could Slow Progression of Memory Loss
    Lithium treatment helps slow the progression of memory loss, according to new research, published in the British Journal of Psychiatry. The finding raises the possibility that lithium could one day be used to prevent Alzheimer’s disease.
  • New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy
    Cancer Research Technology, Merck Serono, Cancer Research UK, Cardiff University and The Institute of Cancer Research are set to begin a new research collaboration that will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.
  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Catching up on Circulating Tumor Cell Technology
    Circulating tumor cells (CTCs) are cells that ‘escape’ from primary tumor cells and migrate into the bloodstream, where they circulate through the body. CTCs were first identified in the 1980s as cells that had the morphology of tumor cells but were found in the blood. Over the past two decades technological innovations have eased the detection and analysis of CTCs. The resulting investigations of CTCs are an important area of clinical research because they are demonstrating that CTCs have potential clinical value as warning signals of cancer progression.

Top 5 Stories

News

Omega-3 preparation protects against bowel polyps

18 March 2010

A new preparation of an omega-3 polyunsaturated fatty acid found naturally in fish could offer hope for thousands of patients at risk of developing an inherited form of bowel cancer.

A team of investigators, led by Professor Mark Hull from the University of Leeds, studied patients diagnosed with the rare inherited condition familial adenomatous polyposis (FAP), thought to be responsible for approximately one in every 100 bowel cancers.

Scientists observed a significant reduction in the size and number of pre-cancerous growths, or polyps, during a six month trial of the omega-3 preparation. Now Professor Hull and his team say that further research is needed to find out whether this new agent, eicosapentaenoic acid (EPA), could help prevent the non-hereditary form of bowel cancer, which is the third most common cancer in the UK and is diagnosed in approximately 37,000 people each year.

FAP causes a large number of polyps to form in the lining of the large bowel. Patients usually undergo bowel surgery but remain at risk of developing polyps and cancer in any remaining bowel, so regular endoscopic (camera test) checks are required.

Professor Hull said: ‘A safe and effective drug therapy may reduce the number of invasive check-up procedures, which can be unpleasant and always involve a small amount of risk.

During a randomized, placebo-controlled trial, the team observed the condition of 55 patients over six months. Twenty-eight patients were given 2 grams daily of a new, highly purified formulation of the omega-3 polyunsaturated fatty acid EPA (‘Alfa’). Researchers observed a significant reduction in the number and size of polyps in this group, whereas the placebo group showed an increase in polyp number and size over the same period.

‘The particular preparation of EPA that we used delivers approximately four times as much beneficial polyunsaturated fatty acid per day as is derived from eating two to three portions of fish a week. The drug is also designed to be released into the small intestine, minimising nausea and halitosis often associated with taking over-the-counter fish oil supplements,’ said Professor Hull.

The paper ‘Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis’ is published in GUT.

 

This article is featured in:
Biotherapeutics  •  Drug Trials

 

Comment on this article

You must be registered and logged in to leave a comment about this article.

Copyright © 2012
Elsevier Ltd. All rights reserved.
Terms & Conditions | Privacy | Website Design Working with water